Cost Comparison of Flash Continuous Glucose Monitoring with Self-monitoring of Blood Glucose in Adults with Type 1 or Type 2 Diabetes Using Intensive Insulin—From a US Private Payer Perspective

Q4 Medicine
Lizheng Shi, R. Hellmund
{"title":"Cost Comparison of Flash Continuous Glucose Monitoring with Self-monitoring of Blood Glucose in Adults with Type 1 or Type 2 Diabetes Using Intensive Insulin—From a US Private Payer Perspective","authors":"Lizheng Shi, R. Hellmund","doi":"10.17925/use.2020.16.1.24","DOIUrl":null,"url":null,"abstract":"Objective: Estimate the costs associated with a flash continuous glucose monitoring system as a replacement for self-monitoring of blood glucose (SMBG) for people using intensive insulin to manage diabetes, from a US private payer perspective. Methods: The base case used SMBG at 8 tests/day, the mid-point of the range recommended by the American Diabetes Association for intensive insulin users. Scenario analyses used SMBG at 3, 6 and 10 tests/day. Estimated costs of glucose monitoring and severe hypoglycemic events were assessed. Results: For the base case, the annual cost of SMBG was $4,380 for a patient with type 1 diabetes mellitus (T1DM) compared with $1,712 for flash monitoring, a reduction of $2,667 (61%). The cost of flash monitoring was also lower than SMBG at 6 and 10 tests/day. With SMBG at 3 tests/day the cost was comparable. Similar results were obtained for patients with T2DM using intensive insulin. The annual cost of severe hypoglycemia was approximately 50% less for flash monitoring than for SMBG for both patients with T1DM and those with T2DM. Conclusions: For US private payers, the flash monitoring system provides cost savings compared with SMBG for people with diabetes using intensive insulin. Cost savings with flash glucose monitoring may be realized through a reduction in severe hypoglycemia. Further study of budget impact is needed to include changes in behavior leading to improved adherence.","PeriodicalId":23490,"journal":{"name":"US endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"US endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/use.2020.16.1.24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 5

Abstract

Objective: Estimate the costs associated with a flash continuous glucose monitoring system as a replacement for self-monitoring of blood glucose (SMBG) for people using intensive insulin to manage diabetes, from a US private payer perspective. Methods: The base case used SMBG at 8 tests/day, the mid-point of the range recommended by the American Diabetes Association for intensive insulin users. Scenario analyses used SMBG at 3, 6 and 10 tests/day. Estimated costs of glucose monitoring and severe hypoglycemic events were assessed. Results: For the base case, the annual cost of SMBG was $4,380 for a patient with type 1 diabetes mellitus (T1DM) compared with $1,712 for flash monitoring, a reduction of $2,667 (61%). The cost of flash monitoring was also lower than SMBG at 6 and 10 tests/day. With SMBG at 3 tests/day the cost was comparable. Similar results were obtained for patients with T2DM using intensive insulin. The annual cost of severe hypoglycemia was approximately 50% less for flash monitoring than for SMBG for both patients with T1DM and those with T2DM. Conclusions: For US private payers, the flash monitoring system provides cost savings compared with SMBG for people with diabetes using intensive insulin. Cost savings with flash glucose monitoring may be realized through a reduction in severe hypoglycemia. Further study of budget impact is needed to include changes in behavior leading to improved adherence.
1型或2型糖尿病患者使用强化胰岛素的快速连续血糖监测与自我血糖监测的成本比较——来自美国私人支付者的观点
目的:从美国私人支付者的角度估计使用快速连续血糖监测系统替代自我血糖监测(SMBG)对使用强化胰岛素治疗糖尿病患者的相关成本。方法:基础病例使用8次/天的SMBG,这是美国糖尿病协会推荐的胰岛素密集使用者范围的中点。场景分析使用SMBG进行3次、6次和10次测试/天。评估了血糖监测和严重低血糖事件的估计成本。结果:在基本病例中,1型糖尿病(T1DM)患者SMBG的年成本为4,380美元,而闪光监测的年成本为1,712美元,减少了2,667美元(61%)。闪光灯监测的成本也低于SMBG,每天测试6次和10次。SMBG每天测试3次,成本相当。T2DM患者使用强化胰岛素也获得了类似的结果。对于1型糖尿病和2型糖尿病患者,快速监测严重低血糖的年成本比SMBG低约50%。结论:对于美国私人支付者来说,与使用强化胰岛素的糖尿病患者相比,闪光监测系统可以节省成本。快速血糖监测可以通过减少严重低血糖来节省成本。需要进一步研究预算的影响,以包括行为的改变,从而提高依从性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
US endocrinology
US endocrinology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
1.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信